
ZBIO
Zenas BioPharma Inc.
$26.65
+$0.06(+0.23%)
70
Overall
80
Value
91
Tech
39
Quality
Market Cap
$878.00M
Volume
236.27K
52W Range
$5.83 - $29.73
Target Price
$35.50
Order:
Income Statement
Metric | Trend | Chart | 2023 Dec | 2024 Dec |
---|---|---|---|---|
REVENUE | ||||
Total Revenue | $50.0M | $5.0M | ||
Total Revenue | $50.0M | $5.0M | ||
GROSS PROFIT | ||||
Gross Profit | $50.0M | $5.0M | ||
OPERATING EXPENSES | ||||
Operating Expenses | $87.1M | $168.9M | ||
Research & Development | $70.0M | $139.1M | ||
Research Expense | $70.0M | $139.1M | ||
Selling, General & Administrative | $17.1M | $29.7M | ||
General & Administrative Expenses | $17.1M | $29.7M | ||
OPERATING INCOME | ||||
Operating income | $-37.1M | $-163.9M | ||
EBITDA | $-36.7M | $-156.4M | ||
NON-OPERATING ITEMS | ||||
Other Income/Expense | $-324.0K | $-8.2M | ||
Other Special Charges | $324.0K | $8.2M | ||
PRE-TAX INCOME | ||||
EBIT | $-36.8M | $-156.6M | ||
Pre-Tax Income | $-36.8M | $-156.6M | ||
INCOME TAX | ||||
Tax Provision | $301.0K | $429.0K | ||
NET INCOME | ||||
Net Income | $-37.1M | $-157.0M | ||
Net Income (Continuing Operations) | $-37.1M | $-157.0M | ||
Net Income (Discontinued Operations) | $-37.1M | $-157.0M | ||
Net Income (Common Stockholders) | $-37.1M | $-157.0M | ||
Normalized Income | $-27.1M | $-155.0M | ||
TOTALS | ||||
Total Expenses | $87.1M | $168.9M | ||
SHARE & EPS DATA | ||||
Average Shares Outstanding | $13.3M | $13.2M | ||
Average Shares Outstanding (Diluted) | $13.3M | $13.2M | ||
Shares Outstanding | $42.1M | $41.8M | ||
Basic EPS | -- | $-11.89 | ||
Basic EPS (Continuing Operations) | -- | $-11.89 | ||
Diluted EPS | -- | $-11.89 | ||
Diluted EPS (Continuing Operations) | -- | $-11.89 | ||
OTHER METRICS | ||||
Other Gand A | $17.1M | $29.7M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | ZBIO | $26.65 | +0.2% | 236.27K |
3 | ||||
4 | ||||
5 | ||||
6 |